Miller C L, Longnecker R, Kieff E
Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115.
J Virol. 1993 Jun;67(6):3087-94. doi: 10.1128/JVI.67.6.3087-3094.1993.
LMP2A is expressed in latent Epstein-Barr virus (EBV) infection and interacts with LMP1 and members of the src tyrosine kinase family in the plasma membrane. Since tyrosine kinase mediate receptor-induced changes in intracellular free calcium, the effect of LMP2A on receptor-mediated intracellular calcium mobilization was evaluated by stably expressing LMP2A in an EBV-negative Burkitt tumor cell line (BJAB) or in LMP1-converted BJAB cells. LMP2A significantly blocked calcium mobilization following class II, CD19, or immunoglobulin M cross-linking. LMP2A effects were partially reversed in LMP1-converted cell lines. These results are compatible with LMP2A acting in latent B-lymphocyte infection to downmodulate LMP1 effects on cell growth or to inhibit induction of lytic EBV infection in specific human tissues following receptor ligation.
LMP2A在潜伏性EB病毒(EBV)感染中表达,并在质膜中与LMP1及src酪氨酸激酶家族成员相互作用。由于酪氨酸激酶介导受体诱导的细胞内游离钙变化,因此通过在EBV阴性的伯基特肿瘤细胞系(BJAB)或LMP1转化的BJAB细胞中稳定表达LMP2A,评估LMP2A对受体介导的细胞内钙动员的影响。LMP2A显著阻断了II类、CD19或免疫球蛋白M交联后的钙动员。在LMP1转化的细胞系中,LMP2A的作用部分逆转。这些结果与LMP2A在潜伏性B淋巴细胞感染中发挥作用,下调LMP1对细胞生长的影响,或在受体连接后抑制特定人类组织中EBV裂解感染的诱导作用相一致。